Hospitech Respiration: Strategizing on Prevention for Cure
Yoav Venkert, CEO
Generally, ventilated patients remaining in the ICU for more than two-three days tend to develop ventilator-associated complications. Ventilator-Associated Respiratory Infection (VARI) and Ventilator-Associated-Pneumonia(VAP) occurs when the airway's cuff is not sufficiently inflated and subglottic secretions from the oral cavity leak into the lungs, and injury of the tracheal tissue due to over-inflation of the cuff. The AnapnoGuard system (AG100 control unit and AG ETT), developed by Hospitech Respiration, is designed to prevent such complications.
Going by the belief that 'prevention is better than cure,' Hospitech's team adopts a therapeutic approach to innovating devices that reduce complications among mechanically ventilated patients. The Israel-based company develops, manufactures, and markets advanced medical devices for airway management to help promote patient safety and reduce complications in mechanically ventilated patients. Hospitech’s devices are aimed at easing out the difficulties and reducing the intensive workload that the clinical teams are facing while treating mechanically ventilated patients.
Unlike other manually operated or automated devices in the market, Hospitech Respiration leads the way with their AnapnoGuard System, consisting of the AG100 control unit and the AG ETT, which takes care of two vital requisites. It monitors the leaks around the cuff and sets the optimal cuff pressure for each patient and specific conditions so that no oral secretions or gastric content reaches the lungs. Moreover, it also prevents critical injury to the tracheal tissue, which may occur due to the application of excessive cuff pressure. “Our device is the only one in the market that continuously monitors the leaks around the airway cuff and provides automatic adjustment of the cuff pressure in accordance with patient conditions to ensure sealing at the minimal required pressure,” says Yoav Venkert, CEO of Hospitech Respiration.
At the heart of the company’s advanced airway management is the AG100s Control Unit.
The AG100s Control Unit has an automated closed-loop leakage detection and cuff pressure control algorithm based on monitoring the CO2 level above the cuff as an indication of leakage. The AG multi lumen Endotracheal Tube (AG ETT) is comprised of two suction lumens, and venting/ rinsing lumen is attached to the AG100s Control Unit and allows CO2 sampling as well as the effective evacuation of subglottic secretions by simultaneous venting and suction or rinsing and suction of subglottic secretions.
The AnapnoGuard system is the only device in the market that combines the two functions of cuff pressure control and evacuation of subglottic secretions
“The AG100s system uses the most effective methods to remove subglottic secretions and clean the trachea. It combines the functions of two devices. Cuff pressure controllers and suction regulators) that operate automatically in a synchronized manner,” says Venkert.
Hospitech’s innovative solution encompasses more products such as AG CUFFILL, easy to use, manual, syringe-like manometer for cuff pressure management. The Platform of solutions offered by Hospitech Respiration provides the clinicians with tools to improve airway management care at any setting.
Out of hundreds of patients successfully treated by the AnapnoGuard system in Israel, China, Europe, and the U.S., Venkert cites a recently published case from the Mayo Clinic, FL. A 53-years-old patient undergoing lung transplantation was given the support of a left-sided doublelumen tube (DLT). Before leaving the operating room, the DLT was substituted with multi lumen AnapnoGuard ETT and the patient was transferred to the ICU on a transport ventilator. Being connected to the AG100s system for protective airway management, the patient stayed on for four days without complications and was successfully decannulated.
On an innovation spree, the company is coming up with more path-breaking solutions for ventilated patients. “Our comprehensive understanding of the marketplace stemming from our direct relationships with various healthcare providers and "foots on the ICU floor" contributes significantly to the success of the solution," states Venkert. Hospitech is on its path to make AnapnoGuard system a standard of care solution for high risk ventilated patient populations in ICU settings and the AG Cuffill the standard of care for EMS, home care, and general ventilated patients in the ICU.
Description Founded in 2006, Hospitech Respiration Ltd is committed to the development and commercialization of innovative medical devices, aimed at enhancing the quality of care, promoting patient safety and reducing complications in mechanically ventilated patients.
Based in Israel and led by a highly experienced team, the company holds a broad IP portfolio and its commercial innovative solution, consists of a platform of automated, as well as disposable devices
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: